A recent study has raised concerns about the cardiovascular safety of two commonly prescribed classes of drugs for type 2 diabetes: sulfonylureas and basal insulin. These medications, often used as second-line treatments after metformin, have been associated with a higher risk of heart attack, stroke, and heart failure compared to newer diabetes medications.
Key Takeaways
- Two common type 2 diabetes drug classes, sulfonylureas and basal insulin, are linked to increased cardiovascular risks.
- These drugs are frequently prescribed after metformin when blood sugar control is insufficient.
- Newer diabetes medications, such as DPP-4 inhibitors, GLP-1 agonists, and SGLT-2 inhibitors, appear to have more favorable cardiovascular profiles.
- Healthcare providers are urged to consider these findings when prescribing diabetes treatments.
Understanding the Risks
The study, published in JAMA Network Open, analyzed data from over 130,000 patients with type 2 diabetes initiating second-line treatment. Researchers found that patients taking sulfonylureas had a 36% higher likelihood of experiencing cardiovascular events, while those on basal insulin were twice as likely to face such events, including heart attack, stroke, heart failure hospitalization, or even amputation.
These findings are particularly significant as sulfonylureas and basal insulin are prescribed to a substantial portion of patients needing a second-line diabetes medication, with some reports indicating they are used by up to 60% of such individuals. The study suggests that for every 103 people treated with sulfonylureas over two years, one cardiovascular event might be observed, and for basal insulin, this number drops to 37 people.
Shifting Treatment Paradigms
In contrast, newer classes of diabetes drugs, including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors, were not associated with increased cardiovascular harm when compared to DPP-4 inhibitors, which are considered to have a neutral effect on cardiovascular outcomes. While these newer medications are often more expensive, experts suggest they may offer a safer alternative for managing type 2 diabetes, especially for patients with existing cardiovascular risk factors.
Lead author Dr. Matthew O’Brien emphasized the need for a “paradigm shift” in diabetes treatment, urging healthcare providers to consider the cardiovascular implications of medication choices early in the treatment course. The study highlights that while these newer drugs may not always demonstrate significant cardiovascular benefits in observational studies as they do in randomized trials for patients with established cardiovascular disease, they do not appear to carry the same risks as sulfonylureas and basal insulin.
Patient and Provider Considerations
This research underscores the importance of personalized medicine in diabetes management. While glipizide (a sulfonylurea) and other drugs in its class have been effective in lowering blood sugar for decades, the potential for increased cardiovascular risk warrants careful consideration. Patients are advised to discuss their current diabetes medications with their healthcare providers to ensure they are on the most appropriate and safest treatment plan for their individual health needs.
Sources
- Common diabetes drug linked to heart disease: This is what the study says, Times of India.
- Two Type 2 Diabetes Drugs Linked to Higher Risk of Heart Disease, Northwestern University.
- Common diabetes drugs linked to higher heart disease risk, AJC.com.
- Common Diabetes Drugs Linked to Higher Risk of Heart Attack and Stroke, Diabetes In Control.
- Two common diabetes drugs linked to heart attack, stroke risk, UPI.com.